4.7 Review

Applying nanomedicine in maladaptive inflammation and angiogenesis

期刊

ADVANCED DRUG DELIVERY REVIEWS
卷 119, 期 -, 页码 143-158

出版社

ELSEVIER
DOI: 10.1016/j.addr.2017.05.009

关键词

Monocytes; Macrophages; Chronic inflammation; Immunomodulation; Atherosclerosis; Cancer; Angiogenesis; Nanomedicine; Molecular imaging; Targeted drug delivery

资金

  1. National Institutes of Health [R01 EB009638, R01 HL071021, R01 HL128056, P01 HL131478, R01 HL125703, R01 HL118440]
  2. American Heart Association [16SDG31390007]
  3. Netherlands Organisation for Scientific Research NWO Vidi
  4. European Framework Program 7 grant [FP7-Health 309820: NanoAthero]
  5. Dutch network for Nanotechnology NanoNext NL in the subprogram Drug Delivery

向作者/读者索取更多资源

Inflammation and angiogenesis drive the development and progression of multiple devastating diseases such as atherosclerosis, cancer, rheumatoid arthritis, and inflammatory bowel disease. Though these diseases have very different phenotypic consequences, they possess several common pathophysiological features in which monocyte recruitment, macrophage polarization, and enhanced vascular permeability play critical roles. Thus, developing rational targeting strategies tailored to the different stages of the journey of monocytes, from bone marrow to local lesions, and their extravasation from the vasculature in diseased tissues will advance nanomedicine. The integration of in vivo imaging uniquely allows studying nanoparticle kinetics, accumulation, clearance, and biological activity, at levels ranging from subcellular to an entire organism, and will shed light on the fate of intravenously administered nanomedicines. We anticipate that convergence of nanomedicines, biomedical engineering, and life sciences will help to advance clinically relevant therapeutics and diagnostic agents for patients with chronic inflammatory diseases. (C) 2017 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据